Abstract

s / Biol Blood Marrow Transplant 20 (2014) S165eS183 S178 (HSCT). Outcomes with myelaoblative conditioning have been surprisingly poor with almost 1/3 of patients succumbing to early transplant related mortality (TRM). Most of the fatalities occur due to cardiopulmonary failure. Mortality is higher than that in other immunodeficiency syndromes, however the reasons for this increased toxicity are unclear. We hypothesized that prolonged steroid exposure during HLH therapy may cause the development of cardiac hypertrophy. Compromised cardiac reserve could contribute to poor outcome because of the multiple physiological stressors associated with transplant. We reviewed the records of 11 consecutive children undergoing HSCT at our institution from January 2004December 2012. The age at diagnosis ranged from birth to 60 (median 2.5) months and the age at HSCT from 6-70 (median 9) months. 8/11 had identified genetic defects (5 perforin, 2 MUNC, 1 Griscelli). All 11 received pre-HSCT therapy with etoposide, cyclosporin and dexamethasone. 10/11 were in complete disease remission at the time of HSCT. Conditioning was fully ablative in 9/11(Bu, Cy, VP, ATG) and reduced intensity in 2 (Flu/campath). 6 received marrow as stem cell source. Donors were matched sibling in 1, and unrelated donor in 5. 5 received unrelated umbilical cord. All patients except the sibling donor received methylprednisonole at 1-2 mg/kg/day as GVHD prophylaxis. 3 had acute GVHD and received additional therapy with high dose (>2 mg/kg/day) steroids. Pre transplantation echocardiograms were accessible for 6 patients; none had evidence of LVH. Post transplantation echocardiograms were reviewed for all patients. 7/11 (64%) never evidenced LVH at any point post-HSCT. TRM in this group was 3/7 (42%) due to multi-organ system failure (MOSF) (2) and adenovirus infection (1). 4/11 patients (36%) developed LVH 1 18weeks post-HSCT. TRMwas 100% in this group, higher than thosewithout LVH (p1⁄40.58) and all due to MOSF. Infectious agents were only identified in /4 (adeno / EBV) and recurrent HLH in one. In light of these findings, particular attention to cardiac status in patients with HLH is highly recommended. Further investigation is needed to identify pre and post SCT factors contributing to cardiac hypertrophy. This will allow both preventativemeasures to be developed and optimalmanagement to be provided when these patients become critically ill.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.